home / stock / kdny / kdny news

KDNY News and Press, Chinook Therapeutics Inc Com From 04/12/22

Stock Information
Company Name: Chinook Therapeutics Inc Com
Stock Symbol: KDNY
Market: NASDAQ
Website: chinooktx.com
Menu
KDNY KDNY Quote KDNY Short KDNY News KDNY Articles KDNY Message Board
Get KDNY Alerts

News, Short Squeeze, Breakout and More Instantly...
KDNY - Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical tri...
KDNY - Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, president and chief executive office...

KDNY - Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A (IgA) nephropathy and engage key medic...

KDNY - BNR, URGN and PRPL among after hour movers

Gainers: Burning Rock Biotech Limited (BNR) +5%. Hemisphere Media Group (HMTV) +4%. Neuronetics  (STIM) +4%. AvePoint  (AVPT) +3%. Jounce Therapeutics (JNCE) +3%. Losers: UroGen Pharma (URGN) -12%. Purple Innovation  (PRPL) -5%. Trinity Capital  (TRIN) -4%. ...
KDNY - Tracking Baker Brothers Portfolio - Q4 2021 Update

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

KDNY - Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors

SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A....

KDNY - Chinook Therapeutics GAAP EPS of -$2.26, revenue of $51.62M

Chinook Therapeutics press release (NASDAQ:KDNY): FY GAAP EPS of -$2.26. Revenue of $51.62M (+6195.1% Y/Y). For further details see: Chinook Therapeutics GAAP EPS of -$2.26, revenue of $51.62M

KDNY - Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the ...

KDNY - Chinook Therapeutics to Present at Oppenheimer's 32nd Annual Healthcare Conference

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a...

KDNY - Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit

SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4 th Annual Chronic Kid...
Previous 10 Next 10